Adocia ADR ADOCY
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $9.80
- Day Range
- $11.80–11.80
- 52-Week Range
- $11.80–11.80
- Bid/Ask
- $0.00 / $14.22
- Market Cap
- $95.48 Mil
- Volume/Avg
- 760 / 760
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 111.56
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Adocia is a clinical-stage biotechnology company. It specializes in the development of formulations of already approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. The firm has developed Biochaperone, a proprietary technology platform to enhance the effectiveness of therapeutic proteins. The company's clinical pipeline includes Biochaperone Lispro, Biochaparone Combo, Biochaparone Glucagon, and others. Its pre-clinical pipeline includes BioChaperone LisPram, BioChaperone Glargine GLP-1, and BioChaperone Glucagon GLP1. Its patent portfolio mainly consists of chronic wound healing, insulin therapy, and monoclonal antibodies.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 107
- Website
- https://www.adocia.com
Valuation
Metric
|
ADOCY
|
---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 111.56 |
Price/Cash Flow | — |
Price/Earnings
ADOCY
Financial Strength
Metric
|
ADOCY
|
---|---|
Quick Ratio | 0.57 |
Current Ratio | 0.60 |
Interest Coverage | −6.09 |
Quick Ratio
ADOCY
Profitability
Metric
|
ADOCY
|
---|---|
Return on Assets (Normalized) | −58.15% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −79.63% |
Return on Assets
ADOCY
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Ylnbvfwct | Xkjgl | $570.1 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Zggmqhh | Xmnwtb | $108.0 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Swwlpphfc | Bbstq | $105.6 Bil | |
MRNA
| Moderna Inc | Pgpmlvpx | Nxmv | $40.8 Bil | |
BNTX
| BioNTech SE ADR | Njyzngcq | Sydrb | $21.9 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Gmpvdhy | Qzkhvm | $18.8 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Xqtmbgwzh | Mftdyk | $16.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ylwqllnw | Wygjgd | $13.6 Bil | |
INCY
| Incyte Corp | Spvgqxxf | Xblfnp | $12.8 Bil | |
UTHR
| United Therapeutics Corp | Rbzvktms | Wcjg | $10.8 Bil |